C-peptide: New findings and therapeutic possibilities

Diabetes Research and Clinical Practice

Volumn 107, Issue 3, 2015, Pages 309-319

  Wahren, John ^a,b   Larsson, Charlotte ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cebix AB   (Sweden)

Author keywords

ENOS; Na+, K+ ATPase; Nephropathy; Neuropathy; Reactive oxygen species; Retinopathy

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); C PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MEMBRANE RECEPTOR; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ANTIINFLAMMATORY AGENT; NOS3 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; BLOOD FLOW; BLOOD RHEOLOGY; CELL MEMBRANE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTRACELLULAR SIGNALING; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; ANIMAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DRUG EFFECTS; MALE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; C-PEPTIDE; CELL MEMBRANE; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; HUMANS; MALE; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION;

EID: 84924144349     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.01.016     Document Type: Review

References (67)

1. Steiner D.F., Cunningham D., Spigelman L., Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967, 157:697-700.
2. Henriksson M., Nordling E., Melles E., Shafqat J., Stahlberg M., Ekberg K., et al. Separate functional features of proinsulin C-peptide. Cell Mol Life Sci 2005, 62:1772-1778.
3. Rigler R., Pramanik A., Jonasson P., Kratz G., Jansson O.T., Nygren P., et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA 1999, 96:13318-13323.
4. Landreh M., Ostberg L.J., Jornvall H. A subdivided molecular architecture with separate features and stepwise emergence among proinsulin C-peptides. Biochem Biophys Res Commun 2014, 450:1433-1438.
5. Bathgate R.A., Halls M.L., van der Westhuizen E.T., Callander G.E., Kocan M., Summers R.J. Relaxin family peptides and their receptors. Physiol Rev 2013, 93:405-480.
6. Polonsky K.S., Given B.D., Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988, 81:442-448.
7. Faber O.K., Hagen C., Binder C., Markussen J., Naithani V.K., Blix P.M., et al. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 1978, 62:197-203.
8. Henriksen J.H., Tronier B., Bulow J.B. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 1987, 36:463-468.
9. Melles E., Jornvall H., Tryggvason S., Danielsson K.G., Ekberg K., Tryggvason K., et al. Degradation of proinsulin C-peptide in kidney and placenta extracts by a specific endoprotease activity. Cell Mol Life Sci 2004, 61:2979-2982.
10. Panero F., Novelli G., Zucco C., Fornengo P., Perotto M., Segre O., et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009, 32:301-305.
11. Steffes M.W., Sibley S., Jackson M., Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26:832-836.
12. Boggi U., Rosati C.M., Marchetti P. Follow-up of secondary diabetic complications after pancreas transplantation. Curr Opin Organ Transplant 2013, 18:102-110.
13. Johansson B.L., Sjöberg S., Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992, 35:121-128.
14. Johansson B.L., Kernell A., Sjöberg S., Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 1993, 77:976-981.
15. Johansson B.L., Borg K., Fernqvist-Forbes E., Odergren T., Remahl S., Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996, 39:687-695.
16. Ohtomo Y., Aperia A., Sahlgren B., Johansson B.L., Wahren J. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996, 39:199-205.
17. Al-Rasheed N.M., Willars G.B., Brunskill N.J. C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol 2006, 17:986-995.
18. Yosten G.L., Kolar G.R., Redlinger L.J., Samson W.K. Evidence for an interaction between proinsulin C-peptide and GPR146. J Endocrinol 2013, 218:B1-B8.
19. Johansson B.L., Linde B., Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992, 35:1151-1158.
20. Wallerath T., Kunt T., Forst T., Closs E.I., Lehmann R., Flohr T., et al. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003, 9:95-102.
21. Zhong Z., Kotova O., Davidescu A., Ehren I., Ekberg K., Jörnvall H., et al. C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci 2004, 61:2782-2790.
22. Al-Rasheed N.M., Meakin F., Royal E.L., Lewington A.J., Brown J., Willars G.B., et al. Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia 2004, 47:987-997.
23. Kitamura T., Kimura K., Jung B.D., Makondo K., Okamoto S., Canas X., et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J 2001, 355:123-129.
24. Al-Rasheed N.M., Chana R.S., Baines R.J., Willars G.B., Brunskill N.J. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 2004, 279:49747-49754.
25. Scalia R., Coyle K.M., Levine B.J., Booth G., Lefer A.M. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J 2000, 14:2357-2364.
26. Kitamura T., Kimura K., Makondo K., Furuya D.T., Suzuki M., Yoshida T., et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003, 46:1698-1705.
27. Galuska D., Pirkmajer S., Barres R., Ekberg K., Wahren J., Chibalin A.V. C-Peptide increases Na, K-ATPase expression via PKC- and MAP kinase-dependent activation of transcription factor ZEB in human renal tubular cells. PLoS ONE 2011, 6:e28294.
28. +-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 2000, 98:283-290.
29. Fiorina P., Folli F., Zerbini G., Maffi P., Gremizzi C., Di Carlo V., et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003, 14:2150-2158.
30. Bhatt M.P., Lim Y.C., Kim Y.M., Ha K.S. C-peptide activates AMPKalpha and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes. Diabetes 2013, 62:3851-3862.
31. Cifarelli V., Geng X., Styche A., Lakomy M., Trucco M., Luppi P. C-peptide reduces high glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation. Diabetologia 2011, 54:2702-2712.
32. Bhatt M.P., Lim Y.C., Hwang J., Na S., Kim Y.M., Ha K.S. C-Peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes 2013, 62:243-253.
33. Luppi P., Kallas A., Wahren J. Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes. Diabetes Metab Res Rev 2013, 29:357-362.
34. Lim Y.C., Bhatt M.P., Kwon M.H., Park D., Lee S., Choe J., et al. Prevention of VEGF-mediated microvascular permeability by C-peptide in diabetic mice. Cardiovasc Res 2014, 101:155-164.
35. Hills C.E., Willars G.B., Brunskill N.J. Proinsulin C-peptide antagonizes the profibrotic effects of TGF-beta1 via up-regulation of retinoic acid and HGF-related signaling pathways. Mol Endocrinol 2010, 24:822-831.
36. Maezawa Y., Yokote K., Sonezaki K., Fujimoto M., Kobayashi K., Kawamura H., et al. Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev 2006, 22:313-322.
37. Lindenblatt N., Braun B., Menger M.D., Klar E., Vollmar B. C-peptide exerts antithrombotic effects that are repressed by insulin in normal and diabetic mice. Diabetologia 2006, 49:792-800.
38. Luppi P., Cifarelli V., Tse H., Piganelli J., Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 2008, 51:1534-1543.
39. Haidet J., Cifarelli V., Trucco M., Luppi P. C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia. Inflamm Res 2012, 61:27-35.
40. Mughal R.S., Scragg J.L., Lister P., Warburton P., Riches K., O'Regan D.J., et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 2010, 53:1761-1771.
41. Sima A.A., Zhang W., Sugimoto K., Henry D., Li Z., Wahren J., et al. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia 2001, 44:889-897.
42. Cotter M.A., Ekberg K., Wahren J., Cameron N.E. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003, 52:1812-1817.
43. Stevens M.J., Zhang W., Li F., Sima A.A. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004, 287:E497-E505.
44. Sima A.A., Brismar T. Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 1985, 18:21-29.
45. Ido Y., Vindigni A., Chang K., Stramm L., Chance R., Heath W.F., et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997, 277:563-566.
46. Dyck P.J., Lambert E.H., O'Brien P.C. Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 1976, 26:466-471.
47. Kamiya H., Zhang W., Sima A.A. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004, 56:827-835.
48. Ekberg K., Brismar T., Johansson B.L., Jonsson B., Lindström P., Wahren J. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003, 52:536-541.
49. Ekberg K., Brismar T., Johansson B.L., Lindstrom P., Juntti-Berggren L., Norrby A., et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007, 30:71-76.
50. Brown M.J., Bird S.J., Watling S., Kaleta H., Hayes L., Eckert S., et al. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 2004, 27:1153-1159.
51. Johansson B.L., Borg K., Fernqvist-Forbes E., Kernell A., Odergren T., Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000, 17:181-189.
52. Krolewski A.S., Warram J.H., Christlieb A.R., Busick E.J., Kahn C.R. The changing natural history of nephropathy in type I diabetes. Am J Med 1985, 78:785-794.
53. Fioretto P., Steffes M.W., Brown D.M., Mauer S.M. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 1992, 20:549-558.
54. Sjöquist M., Huang W., Johansson B.L. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 1998, 54:758-764.
55. Samnegård B., Jacobson S.H., Jaremko G., Johansson B.L., Sjöquist M. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001, 60:1258-1265.
56. Samnegård B., Jacobson S.H., Jaremko G., Johansson B.L., Ekberg K., Isaksson B., et al. C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant 2005, 20:532-538.
57. Nordquist L., Brown R., Fasching A., Persson P., Palm F. Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol 2009, 297:F1265-F1272.
58. Ekberg K., Johansson B.-L., Wahren J. Stimulation of blood flow by C-peptide in patients with type 1 diabetes. Diabetologia 2001, 44(Suppl 1):A323.
59. Lindström K., Johansson C., Johnsson E., Haraldsson B. Acute effects of C-peptide on the microvasculature of isolated perfused skeletal muscles and kidneys in rat. Acta Physiol Scand 1996, 156:19-25.
60. Forst T., Kunt T., Pohlmann T., Goitom K., Engelbach M., Beyer J., et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998, 101:2036-2041.
61. Johansson B.L., Sundell J., Ekberg K., Jonsson C., Seppanen M., Raitakari O., et al. C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab 2004, 286:E14-E19.
62. Hansen A., Johansson B.L., Wahren J., von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002, 51:3077-3082.
63. McMillan D.E., Utterback N.G., La Puma J. Reduced erythrocyte deformability in diabetes. Diabetes 1978, 27:895-901.
64. Kunt T., Schneider S., Pfutzner A., Goitum K., Engelbach M., Schauf B., et al. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia 1999, 42:465-471.
65. Hach T., Forst T., Kunt T., Ekberg K., Pfutzner A., Wahren J. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Exp Diabetes Res 2008, 2008:730594.
66. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
67. Foyt H., Daniels M., Milad M., Wahren J. Pharmacokinetics, safety, and tolerability of a long-acting C-peptide (CBX129801) in patients with type 1 diabetes. Diabetologia 2012, 55:S455.